drugset
drugset / Trial / NCT01733147

Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids

NCT01733147 ↗

Phase 4 Completed 60 enrolled Mayo Clinic
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being done to understand the effect of dietary omega-3 fats in decreasing tissue inflammation in Barrett's esophagus.

Timeline

Start
2012-11
Primary completion
2018-09-12
Completion
2018-09-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omega-3 fatty acids Unknown 1200 mg Oral

Indications

Barrett esophagus obesity disorder